Clinical trials: End-Stage Kidney Disease
Chronic Kidney Disease, End Stage Renal Disease
TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment.
- Trial name
- NCT02117427
- Testing
- MDGN201 TARGTEPO
- Where
- 5 sites in Israel
- Volunteers
- 11 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Chronic Renal Failure
Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug
Chronic renal failure is a syndrome that renal function is decreased, and the patient number is increasing. In addition, patients on dialysis have also increased.
- Trial name
- NCT02378194
- Testing
- HD-003 (800mg/day), HD-003 (1600mg/day)
- Volunteers
- 62 people
- Sponsor
- Hyundai Pharmaceutical Co., LTD.
Endstage Renal Disease
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis.
- Trial name
- ACHIEVE (NCT03020303)
- Testing
- Spironolactone 25Mg Tablet
- Where
- 141 sites in Australia, Brazil and 10 more
- Volunteers
- 2,538 people
- Sponsor
- Hamilton Health Sciences Corporation
Chronic Renal Failure
Study to Determine Appropriate Nurse: Patient Ratios in Peritoneal Dialysis Programs
As the resolution of the Brazilian Federal Council of Nursing (COFEN) sizing the framework of nursing professionals is essential to ensure the safety and quality of patient care.
- Trial name
- NCT02266979
- Where
- Brazil
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ana Elizabeth Prado Lima Figueiredo
End Stage Renal Disease
Effect of Adipokines in Hemodialysis Patients
This is a double blinded randomized clinical trial of pioglitazone vs. placebo in overweight or obese, diabetic and non-diabetic hemodialysis patients.
- Trial name
- NCT01301027
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- University of Utah
Arteriovenous Fistula Stenosis
Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease
A Study on the Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis
- Trial name
- NCT07452822
- Testing
- Human umbilical cord mesenchymal stem cells injection, saline solution
- Volunteers
- 54 people
- Sponsor
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
End Stage Renal Disease (ESRD)
EndoForce Post Approval Study
The goal of this observational study is to collect long-term safety and performance data for the use of the EndoForce System for connecting a hemodialysis graft to a vein in patients with End Stage Renal Disease.
- Trial name
- NCT07146854
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Phraxis, Inc.
End Stage Renal Disease
An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System
This study is designed to monitor and assess the safety of continued access to the HemoCare™ Hemodialysis System used during the review of the pre-market notifications for the devices in the HemoCare™ Hemodialysis System.
- Trial name
- NCT04198012
- Testing
- HemoCare™ Hemodialysis System
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Deka Research and Development
Kidney Failure, Chronic
Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis
The aim of this investigator initated study is to examine the effect of OMACOR (Omega-3-acid ethyl ester 90) on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis, who has previously…
- Trial name
- NCT00257283
- Testing
- Omega-3-acid ethyl esters 90
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Pronova BioPharma
End Stage Renal Disease
Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
The purpose of this study is to evaluate the safety and efficacy of induction therapy with Thymoglobulin in comparison with IL2 receptor antagonists (daclizumab or basiliximab).
- Trial name
- NCT00859131
- Testing
- Rabbit Antithymocyte globulin, Daclizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Medical University of South Carolina
Chronic Renal Disease and Nephrotic Syndrome
Electroencephalographic Changes in Nonconvulsive Children With Chronic Renal Disease
Chronic kidney disease (CKD) arises from many heterogeneous disease pathways that alter the function and structure of the kidney irreversibly, over months or years.
- Trial name
- NCT06185257
- Testing
- EEG
- Volunteers
- 80 people
- Sponsor
- Assiut University
End Stage Renal Failure, Hemodialysis, Fatigue
Reflexology Versus Progressive Muscle Relaxation for Fatigue in Hemodialysis Patients
The goal of this clinical trial is to compare the effects of reflexology and progressive muscle relaxation in reducing fatigue among hemodialysis patients and to determine which intervention provides greater relief from fatigue.
- Trial name
- PMR-HD (NCT07575607)
- Testing
- reflexology, progressive muscle relaxation, Control
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Chronic Kidney Disease Stage 5, Electric Stimulation
Bioeletric Stimulation in Patients With Chronic Kidney Failure
This study aims to evaluate the effects of electrical stimulation on renal function and physical capacity in patients with chronic kidney disease (CKD).
- Trial name
- NCT04608422
- Testing
- Electrical stimulation
- Volunteers
- 20 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Cytomegalovirus (CMV), Kidney Disease
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
The main aim of this study is to assess the safety of maribavir in adults with severe CKD or comorbid ESRD including participants on artificial filtering of the kidney (dialysis) or the blood (hemodialysis).
- Conditions
- Cytomegalovirus (CMV), Kidney Disease, Kidney Failure
- Trial name
- NCT06243731
- Testing
- No Intervention
- Where
- 25 sites in Belgium, Estonia and 5 more
- Volunteers
- 10 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus, End-stage Renal Disease
Liraglutide Treatment to Patients With Severe Renal Insufficiency
Incretin-based therapy for the treatment of patients with type 2 diabetes mellitus (T2D) is new and fundamentally different from the classical treatments with oral antidiabetic agents and insulin.
- Trial name
- NCT01394341
- Testing
- Liraglutide
- Where
- 3 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- Bo Feldt-Rasmussen
Diabetes Mellitus (Diagnosis), End Stage Renal Disease (ESRD)
CGM in Icodextrin PD
Assessment of performance (precision and accuracy) of Simplera™ CGM as compared with a gold standard reference laboratory method (YSI glucose) in diabetes patients on peritoneal dialysis with icodextrin
- Conditions
- Diabetes Mellitus (Diagnosis), End Stage Renal Disease (ESRD), Dialysis, Continuous Glucose Monitoring
- Trial name
- NCT06838819
- Testing
- Continuous glucose monitoring system
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Elaine Chow
Anemia, End Stage Renal Disease
The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability
Hypothesis: Routine clinical tests with feedback control based Epogen(Epo)/Venofer(Iron) protocol will improve Hemoglobin (Hgb) stability and increase the time that patients remain in target Objectives: 1.
- Trial name
- NCT01975844
- Testing
- Individualized Anemia Mangement Protocol
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Michael Germain
End Stage Renal Disease
Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
OBJECTIVES: I. Evaluate whether hemodialysis providing a 2-pool, variable volume urea kinetic modelling value of 1.05 versus 1.45 reduces mortality and morbidity in patients with end stage renal disease. II.
- Trial name
- HEMO (NCT00004285)
- Testing
- Standard dose, low flux hemodialysis, Standard dose, high flux hemodialysis, High dose, low flux hemodialysis
- Where
- United States
- Volunteers
- 1,846 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Renal Disease, Chronic Kidney Disease
Risk Stratification in End Stage Renal Disease (ESRD) - ISAR Study
The purpose of this study is to evaluate the use of non-invasive markers of the autonomic function and micro- and macrocirculation to predict mortality and cardiovascular end points in end-stage renal disease patients.
- Conditions
- End Stage Renal Disease, Chronic Kidney Disease, Cardiovascular Event, Sudden Cardiac Death
- Trial name
- ISAR (NCT01152892)
- Where
- 17 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Technical University of Munich
Anemia, Chronic Kidney Diseases
Effect of rEPO in FGF23 in ESRD Patients
Objective: To evaluate the effects of recombinant Erythropoietin (rEPO) in plasma levels of Fibroblast Growth Factor 23 (FGF23) in End-Stage Renal Disease (ESRD) patients in hemodialysis.
- Trial name
- NCT03803514
- Testing
- Recombinant EPO
- Where
- Chile
- Volunteers
- 60 people
- Sponsor
- University of Chile
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.